Tag Archives: coronary angioplasty

EuroPCR 2019 | Global Leaders: La monoterapia con ticagrelor a largo plazo podría tener un lugar en angioplastias complejas.

EuroPCR 2019 | Global Leaders: Ticagrelor Monotherapy at Long Term Could Have a Role in Complex PCI

EuroPCR 2019 | Global Leaders: Ticagrelor Monotherapy at Long Term Could Have a Role in Complex PCI

This post hoc analysis of what had been a trial with negative outcomes should be considered only as a hypothesis generator. Patients receiving complex PCI treated with ticagrelor monotherapy after one-month dual antiaggregation therapy (DAPT) showed better results at 2 years when compared against patients receiving a conventional DAPT scheme. In the global analysis, this

Salir del quirófano luego de los bypass y requerir angioplastia ¿Qué tan malo puede ser?

PCI Right After CABG: How Bad Can it Be?

In-hospital PCI right after CABG is extremely rare, but it does increase morbidity, mortality and costs significantly. It is still unclear what predictors can be modified to prevent these very early angiography and angioplasty procedures in patients that generally leave the OR with visible EKG changes. Graft failure, distal vascular bed quality, technical error or

ACC 2019 | STOPDAPT-2: Monoterapia con P2Y12 luego de un corto período de doble antiagregación post angioplastia

ACC 2019 | STOPDAPT-2: P2Y12 Monotherapy After Short-Term Dual Antiplatelet Therapy After Angioplasty

Aspirin is against the ropes: first, it was primary prevention; now, its use is being reconsidered even in relation to angioplasty. There might be paradigm changes as regards antiplatelet therapy after angioplasty. These two studies presented at the American College of Cardiology (ACC) 2019 Scientific Session can really change what we have been doing unquestioningly

ACC 2019 | SMART-CHOICE: la aspirina cada vez más “contra las cuerdas”

ACC 2019 | SMART-CHOICE: Aspirin Increasingly “Against the Ropes”

This work (presented during the same American College of Cardiology [ACC] 2019 Scientific Session as the STOPDAPT-2 trial) enrolled 2993 patients who underwent angioplasty with current-generation stents Xience, Promus, Synergy, or Orsiro at 33 Korean sites. Patients were randomized to 12 months of dual antiplatelet therapy or dropping aspirin at 3 months. There was no difference between the short-

ACC 2019 | POET: los antibióticos vía oral con buenos resultados a largo plazo en endocarditis

ACC 2019 | AUGUSTUS: Apixaban Plus P2Y12 Inhibitor Is the Best Combination in Atrial Fibrillation and Angioplasty

Aspirin increases bleeding with no ischemic benefit, but a trend toward more stent thrombosis with placebo warrants further studies. Patients with atrial fibrillation who receive an anticoagulant agent and coronary angioplasty with a stent, and then continue with aspirin, experience an increased risk of bleeding without any ischemic benefit whatsoever.   The use of a

Se rompe el mito de la isquemia silente en los diabéticos

In Diabetics with Multivessel Disease SYNTAX Score Calculations Are Redundant

In diabetic patients with multivessel disease, anatomical complexity assessed by SYNTAX score is an independent predictor of combined events only por PCI patients, and has absolutely no consequence for surgery. The score should not be used to decide on a revascularization strategy. If the patient is diabetic and has multivessel disease, they simply ought to

BVS_everolimus-compressor

Everolimus-Eluting Stents Finally Have a Rival and Not Just a “Non-Inferior” Stent

In this large randomized trial, there were significant differences as regards both target-lesion failure and target-vessel-related infarction, which persisted through a 2-year follow-up and favored treatment with an ultrathin-strut bioresorbable-polymer sirolimus-eluting stent (Orsiro) compared with the gold standard, a durable-polymer everolimus-eluting stent (Xience). Moreover, there were significantly lower rates of target lesion revascularization and late/very

Mortalidad y volumen de angioplastias de un centro ¿Tienen relación?

Predicting Coronary Angioplasty Benefits

Coronary angioplasty or percutaneous coronary intervention (PCI) reduces angina and improves quality of life in patients with stable ischemic cardiomyopathy, though the ORBITA study has shed new light on this. Meanwhile, we will assume this is indeed the case, until new studies either confirm or refute the above mentioned, controversial study. Either way, it is

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

Safety of Combining New Anticoagulant Agents and Dual Antiplatelet Therapy

Atrial fibrillation is the most common arrhythmia and its combination with a history of acute myocardial infarction or coronary angioplasty is quite frequent. According to this study (recently published in JACC), in a real-world population, the combination of direct anticoagulant agents and dual antiplatelet therapy reduces significantly the risk of bleeding and provides similar thromboembolic

perforación coronaria en angioplastia

Practical Management of Coronary Perforations

Coronary perforation has an incidence of 0.5% and it is associated with a 13-fold increase in in-hospital events and a 5-fold increase in 30-day mortality. This event is so catastrophic that its management has become indispensable knowledge to all interventional cardiologists. This accident is most frequently provoked by artery over-dilation caused by a balloon or

Top